John Maslowski
Vermogen: - $ op 31-05-2026
Vermogen: - $ op 31-05-2026
John M.
Maslowski is currently President, Chief Executive Officer & Director at Forge Biologics, Inc. since 2024.
He is Director at Nionyx Bio, Inc. starting in 2025, Director at Dystrophic Epidermolysis Bullosa Research Association of America, Inc. since 2024, and Independent Director at Research Alliance Corp.
IV.
Formerly, Mr. Maslowski was President & Chief Executive Officer at Fibrocell Science, Inc. from 2019 to 2020.
He was Director at Alliance for Regenerative Medicine from 2019 to 2024.
He served as Manager-Quality Assurance Investigations at Wyeth Pharmaceuticals LLC in 2005.
He was Chief Operating Officer at Castle Creek Biosciences, Inc. from 2016 to 2021.
Education includes undergraduate studies at Ursinus College and graduate studies at Villanova University.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
2,27% | 10-07-2026 | 30.000 ( 2,27% ) | 0 $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
Forge Biologics, Inc.
Forge Biologics, Inc. BiotechnologyHealth Technology Operates as a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company | Algemeen Directeur | 01-10-2024 |
Dystrophic Epidermolysis Bullosa Rsch Assoc of America, Inc.
Dystrophic Epidermolysis Bullosa Rsch Assoc of America, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a non-profit organization that provides care and support services for people living with epidermolysis bullosa | Directeur/Bestuurslid | 01-07-2024 |
| Bedrijven | Functie | Einde |
|---|---|---|
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services Promotes legislative, regulatory and reimbursement initiatives for regenerative medicine | Directeur/Bestuurslid | 01-12-2024 |
Castle Creek Biosciences, Inc.
Castle Creek Biosciences, Inc. BiotechnologyHealth Technology Develops gene therapies for patients with skin and genetic diseases | Algemeen Directeur | 20-04-2021 |
| FIBROCELL SCIENCE, INC. | Algemeen Directeur | 01-01-2020 |
Wyeth Pharmaceuticals LLC
Wyeth Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets infant pharmaceutical products | Corporate Officer/Principal | 01-01-2005 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 8 |
|---|---|
Fibrocell Science, Inc.
Fibrocell Science, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as an autologous cell and gene therapy company focused on development of personalized biologics to treat rare skin and connective tissue diseases | Commercial Services |
Wyeth Pharmaceuticals LLC
Wyeth Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets infant pharmaceutical products | Health Technology |
Ursinus College
Ursinus College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Villanova University
Villanova University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dystrophic Epidermolysis Bullosa Rsch Assoc of America, Inc.
Dystrophic Epidermolysis Bullosa Rsch Assoc of America, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a non-profit organization that provides care and support services for people living with epidermolysis bullosa | Commercial Services |
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services Promotes legislative, regulatory and reimbursement initiatives for regenerative medicine | Health Services |
Castle Creek Biosciences, Inc.
Castle Creek Biosciences, Inc. BiotechnologyHealth Technology Develops gene therapies for patients with skin and genetic diseases | Health Technology |
Forge Biologics, Inc.
Forge Biologics, Inc. BiotechnologyHealth Technology Operates as a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau